Walleye Capital
RAPP

Walleye Capital’s Rapport Therapeutics RAPP Stock Holding History

Walleye Capital’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349K Buy
+11,148
New +$314K ﹤0.01% 2948
2025
Q4 		– Sell
-69,570
Closed -$2.07M – 5236
2025
Q3 		$2.07M Buy
+69,570
New +$1.24M 0.01% 1555

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Walleye Capital's RAPP Position: Q1 2026 in Review

Walleye Capital opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 11,148 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #2948 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RAPP as recently as Q3 2025.

Walleye Capital first reported a position in RAPP in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.07M in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Walleye Capital held 11,148 shares of Rapport Therapeutics worth $349K as of Q1 2026.
  • Rapport Therapeutics was a new Walleye Capital position in Q1 2026.
  • Rapport Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2948 holding.
  • Walleye Capital first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Walleye Capital's Rapport Therapeutics position peaked at $2.07M in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.